CTA

Will Nike’s New CFO Reset Expectations Amid Wall Street Scrutiny?

Nike CFO David Denton's charged with supporting "disciplined execution," which has some on Wall Street believing more conservative guidance is ahead.

3 Market-Beating Stocks Worth Your Attention

The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.

Gold Falls on Expectations of Higher for Longer Fed Rates

Warren Buffett Issued a Market Warning That History Says Investors Should Take Seriously

Investors can become their own worst enemies if their expectations aren't grounded in reality.

Foundayo’s Early Growth Is Raising Lilly (LLY)’s Revenue Expectations. But Can It Outrun Pricing Pressure?

Eli Lilly and Company (NYSE:LLY) received a modest price target raise on September 18 from Guggenheim. The brokerage increased its target to $1,284 from $1,273 while maintaining a Buy rating on the pharma stock. But perhaps the more important change was in Foundayo estimates. Guggenheim sharply raised its revenue forecasts for Lilly’s oral obesity drug, […]

Walt Disney vs. Netflix: Which Stock Is a Better Buy in 2026?

One entertainment giant is setting records across its biggest businesses at the same time. The other just guided below expectations and watched its stock drop sharply.

Fed's Hammack worried inflation expectations could deteriorate

How Much Track Is Left For MRVL Stock?

A semiconductor star has posted a large run, but a pullback from its June peak forces every investor to ask if the high-octane growth is already baked into the price.

Microsoft Climbs 4% as Oppenheimer Lifts Target to $570 on Copilot Enterprise Pivot; Alphabet Ticks Up

Oppenheimer just raised its Microsoft target and investors are cheering, but the company's dramatic Copilot overhaul trades predictable subscription revenue for a usage meter that rises and falls with customer behavior. Whether that bet pays off depends on a question Microsoft has not yet answered.

Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data

Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.